-+ 0.00%
-+ 0.00%
-+ 0.00%

Hoth Therapeutics Reports Pipeline Progress Across HT‑001, HT‑KIT, HT‑ALZ And New GDNF Program, Expands IP Portfolio And Partnerships

Benzinga·12/03/2025 19:04:27
Listen to the news

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships.